SDMA

SDMA

• CAS Number: 30344-00-4
• UNSPSC Description: SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
• Target Antigen: Endogenous Metabolite; NF-κB; NO Synthase
• Type: Natural Products
• Related Pathways: Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/SDMA.html
• Purity: 98.0
• Solubility: DMSO : 67.5 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: N[C@@H](CCC/N=C(NC)/NC)C(O)=O
• Molecular Weight: 202.25
• References & Citations: [1]Bode-Böger SM,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent ofcoronary artery disease.|[2]Schepers E, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.Clin J Am Soc Nephrol. 2011 Oct;6(10):2374-83.|[3]Nabity MB, et al. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the EarlyDetection of Chronic Kidney Disease in Dogs. J Vet Intern Med. 2015 Jul-Aug;29(4):1036-44.|[4]Veldink H, et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. Nephrol Dial Transplant. 2013 Jun;28(6):1434-9.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported